| Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 | 09/09 07:00 | globenewswire.com |
| Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript | 08/14 11:43 | seekingalpha.com |
| Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14 | 08/12 07:27 | globenewswire.com |
| Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September | 08/08 08:00 | globenewswire.com |
| Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference | 07/16 07:30 | globenewswire.com |
| Evaxion Reinforces Milestone Timeline and Provides Shareholder Update | 07/03 08:05 | globenewswire.com |
| Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method | 06/26 07:30 | globenewswire.com |
| Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal | 06/17 08:44 | globenewswire.com |
| Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now | 06/13 11:18 | zacks.com |
| Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024 | 06/03 08:00 | globenewswire.com |